November 2008
Worldwide Biotech;Nov2008, Vol. 20 Issue 11, p3
Trade Publication
The article reports on the completion of the recruitment of patients in the pivotal Phase III study of ofatumumab HuMax-CD20 in rituximab refractory follicular non-Hodgkin's lymphoma (NHL) by Genmab A/S. The study has recruited 81 patients receiving treatment at the 1000 milligram (mg) dose level of ofatumumab and an additional 31 patients were recruited at a 500 mg dose level prior to amending the study design. The study aims to determine the efficacy and safety of the drug.


Related Articles

  • Will rituximab replace watchful waiting as the most attractive strategy for treating asymptomatic follicular lymphoma patients? Cabanillas, Fernando; Conners, Joseph M. // Hem/Onc Today;2/10/2011, Vol. 12 Issue 3, p11 

    The article presents views on rituximab replacement of watchful waiting as the most attractive strategy for treating asymptomatic follicular lymphoma patients.

  • Prognostic significance of t(14;18) and bcl-2 gene... Martinka, Magda; Comeau, Terry // Clinical & Investigative Medicine;Dec97, Vol. 20 Issue 6, p364 

    Evaluates whether there is an association between the presence of t(14;18) and bcl-2 gene expression in patients with follicular small cleaved cell lymphoma (FSCCL) and diffuse large cell lymphoma (DLCL). Materials and methods used; Clinical stage at diagnosis and t(14;18); Response to...

  • First-line rituximab good value for NHL in the UK.  // PharmacoEconomics & Outcomes News;1/27/2007, Issue 520, p4 

    The article reports on the cost-effectiveness of using rituximab with cyclophosphamide, vincristine and prednisolone (CVP) in patients with follicular non-Hodgkin's lymphoma (NHL) in Great Britain. According to the results of a Markov model presented at the Annual Meeting and Exposition of the...

  • hematological malignancies.  // Annals of Oncology;Sep2008 Supplement 8, Vol. 19, p229 

    The article presents abstracts on hematological malignancies which include treatment of patients with relapsed, refractory mantle cell lymphoma with temsirolimus, in vitro effects of eltrombopag on proliferation and differentiation of leukemia cell lines, and the use of rituximab and...

  • Non-Hodgkin's Lymphoma Reversal with Dichloroacetate. Flavin, Dana F. // Journal of Oncology;2010, p1 

    In June 2007, a 48-year-old male patient, diagnosed with Stage 4 Non-Hodgkin's Follicular Lymphoma (NHL), was treated for 3 months with conventional chemotherapy resulting in a complete remission. Almost one year later tumors returned in the nasopharynx and neck lymph glands. Refusing all...

  • It's a targeted world in non-Hodgkin's lymphoma. Okosun, Jessica; Fitzgibbon, Jude // British Journal of Nursing;9/22/2011 Supplement, pS28 

    In this article the authors discuss targeted therapies which are used in the treatment of non-Hodgkin's lymphoma. They are supportive of the use of targeted therapies in cancer patients and of research which is being conducted and may be conducted in the future on tumors and which may lead to...

  • Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin®). White, Christine A. // Journal of Experimental Therapeutics & Oncology;2004, Vol. 4 Issue 4, p305 

    Radioimmunotherapy (RIT), in which a radionuclide conjugated to an antibody directed towards a tumor associated antigen (the radioimmunoconjugate) is administered in a therapeutic regimen, represents a significant addition to the treatment of non-Hodgkin's lymphoma (NHL). RIT offers several...

  • Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome. Sano, Takeshi; Sakai, Hisashi; Takimoto, Kengo; Ohno, Hitoshi // International Journal of Clinical Oncology;Feb2007, Vol. 12 Issue 1, p59 

    We report here the case of a 63-year-old man who had a diffuse large B-cell lymphoma associated with hemophagocytic syndrome (HPS). The lymphoma involved the spleen, bilateral adrenal glands, and paraaortic lymph nodes of the abdomen. In both the bone marrow and lymph nodes, hemophagocytosis was...

  • Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. Agustin Avilés; María Nambo; Natividad Neri; Sergio Cleto; Claudia Castañeda; Judith Huerta-Guzmàn; Edgar Murillo; Margarita Contreras; Alejandra Talavera; Martha González // Medical Oncology;Jan2007, Vol. 24 Issue 1, p85 

    Abstract  To assess efficacy and toxicity of rituximab and dose chemotherapy in high-risk diffuse large cell lymphoma, we conducted a controlled clinical trial to assess efficacy and toxicity of a dose-dense regimen CEOP-14 (cyclophosphamide, epirubicin, vincristine, and prednisone every...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics